Geneva, June 20 -- International Clinical Trials Registry received information related to the study (ACTRN12625000632493) titled 'A Phase 1 Safety and Pharmacokinetics Multi Dose Study of GB-hMG in Healthy Women' on June 16.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Primary Sponsor: Accelagen Pty Ltd
Condition:
Infertility
Infertility
Reproductive Health and Childbirth - Fertility including in vitro fertilisation
Intervention:
This is a phase 1, open-label, study to evaluate the safety, pharmacokinetics, and pharmacodynamics 225 IU GB-hMG over 7 consecutive days in healthy premenopausal women.
Twenty eligible, healthy volunteers will receive one (1) daily subcutaneous (SC) injec...